ModiQuest Therapeutics

ModiQuest Therapeutics is a Dutch biotechnology company specializing in the discovery and development of innovative therapeutic antibodies for the treatment of autoimmune diseases and cancer. The company leverages its proprietary technologies, including ModiFuse (electrofusion), ModiSelect (antigen-specific B-cell selection), and ModiXpress (high-throughput antibody expression), to generate high-quality antibodies against difficult targets. A primary focus of their internal pipeline is the development of antibodies targeting citrullinated proteins and the enzymes responsible for citrullination, such as Peptidylarginine Deiminase (PAD), which play a crucial role in the pathogenesis of rheumatoid arthritis. By targeting these specific post-translational modifications, ModiQuest aims to provide highly selective and effective treatments for patients with chronic inflammatory conditions.